Limits...
Quality of life improvement with sublingual immunotherapy: a prospective study of efficacy.

Morris MS, Lowery A, Theodoropoulos DS, Duquette RD, Morris DL - J Allergy (Cairo) (2012)

Bottom Line: The efficacy of SLIT is still debated.Total RQLQ scores also showed significant improvement.This study supports SLIT as a modality effective in controlling allergic symptoms.

View Article: PubMed Central - PubMed

Affiliation: Allergy Associates of La Crosse and Mayo Clinic Health System Franciscan Healthcare-La Crosse-Onalaska, WI 54650, USA.

ABSTRACT
Due to its excellent safety profile, ease of administration, and economic considerations, sublingual immunotherapy (SLIT) is becoming a preferred form of allergen specific immunotherapy. The efficacy of SLIT is still debated. The purpose of this act of practice trial is to evaluate quality of life outcomes in patients treated with SLIT. Fifty one patients with allergic rhinoconjunctivitis demonstrated by skin testing completed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at initiation, at four months and at 10-12 months of SLIT. Significant improvement (P < 0.05) on six of seven domain categories of the RQLQ questionnaire was noted. Total RQLQ scores also showed significant improvement. This study supports SLIT as a modality effective in controlling allergic symptoms.

No MeSH data available.


Related in: MedlinePlus

Participants' aggregate RQLQ scores were compared from their initial appointment and follow-up visits one and two. Statistical significance was achieved within four months of beginning sublingual immunotherapy and continued through their second return visit (Round 3). P < 0.05. Standard error for Round 1 = 7.74, Round 2 = 6.35, and Round 3 = 7.61.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3303579&req=5

fig3: Participants' aggregate RQLQ scores were compared from their initial appointment and follow-up visits one and two. Statistical significance was achieved within four months of beginning sublingual immunotherapy and continued through their second return visit (Round 3). P < 0.05. Standard error for Round 1 = 7.74, Round 2 = 6.35, and Round 3 = 7.61.

Mentions: Paired RQLQ results revealed statistically significant (P < 0.05) improvement in six of seven domains evaluated by the RQLQ after four months of treatment. Improvements were seen in the activities, nonnose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional categories. Results are presented in Table 4. Statistically significant improvements were noted in 23 of the 28 overall questions. Furthermore, the total RQLQ for the whole cohort declined significantly (P < 0.5) from 126.02 to 74.96 within the first four months of treatment (see Figure 3).


Quality of life improvement with sublingual immunotherapy: a prospective study of efficacy.

Morris MS, Lowery A, Theodoropoulos DS, Duquette RD, Morris DL - J Allergy (Cairo) (2012)

Participants' aggregate RQLQ scores were compared from their initial appointment and follow-up visits one and two. Statistical significance was achieved within four months of beginning sublingual immunotherapy and continued through their second return visit (Round 3). P < 0.05. Standard error for Round 1 = 7.74, Round 2 = 6.35, and Round 3 = 7.61.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3303579&req=5

fig3: Participants' aggregate RQLQ scores were compared from their initial appointment and follow-up visits one and two. Statistical significance was achieved within four months of beginning sublingual immunotherapy and continued through their second return visit (Round 3). P < 0.05. Standard error for Round 1 = 7.74, Round 2 = 6.35, and Round 3 = 7.61.
Mentions: Paired RQLQ results revealed statistically significant (P < 0.05) improvement in six of seven domains evaluated by the RQLQ after four months of treatment. Improvements were seen in the activities, nonnose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional categories. Results are presented in Table 4. Statistically significant improvements were noted in 23 of the 28 overall questions. Furthermore, the total RQLQ for the whole cohort declined significantly (P < 0.5) from 126.02 to 74.96 within the first four months of treatment (see Figure 3).

Bottom Line: The efficacy of SLIT is still debated.Total RQLQ scores also showed significant improvement.This study supports SLIT as a modality effective in controlling allergic symptoms.

View Article: PubMed Central - PubMed

Affiliation: Allergy Associates of La Crosse and Mayo Clinic Health System Franciscan Healthcare-La Crosse-Onalaska, WI 54650, USA.

ABSTRACT
Due to its excellent safety profile, ease of administration, and economic considerations, sublingual immunotherapy (SLIT) is becoming a preferred form of allergen specific immunotherapy. The efficacy of SLIT is still debated. The purpose of this act of practice trial is to evaluate quality of life outcomes in patients treated with SLIT. Fifty one patients with allergic rhinoconjunctivitis demonstrated by skin testing completed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at initiation, at four months and at 10-12 months of SLIT. Significant improvement (P < 0.05) on six of seven domain categories of the RQLQ questionnaire was noted. Total RQLQ scores also showed significant improvement. This study supports SLIT as a modality effective in controlling allergic symptoms.

No MeSH data available.


Related in: MedlinePlus